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In 2018, following the availability of new evidence, the World Health Organization (WHO) updated its 29 guidelines on the treatment of drug-resistant tuberculosis (TB) (1). The new guidelines recommend
30
Bedaquiline as core drug in the standard combination regimen for the treatment of rifampicin-resistant TB.
31
As a result, the number of patients eligible to receive bedaquiline-containing regimens would significantly 32 increase. Encouraging results from studies currently underway on the use of bedaquiline in all-oral, shorter-33 course regimens for the treatment of rifampicin-resistant TB could result in an even greater use of 34 bedaquiline in TB control programmes globally (2, 3) . However, solid surveillance of drug-resistance is 35 needed to monitor the emergence of resistance to bedaquiline in patients during therapy.
36
We report first six cases of acquired bedaquiline resistance identified in Pakistan as the results of a 37 surveillance project to monitor acquisition of resistance to bedaquiline implemented by the Pakistan
38
National TB Reference Laboratory (NRL) and TB Supranational Reference Laboratory (SRL-Milan). In 
81
carried P478G mutation in Rv1979c suggesting that this mutation has no effect on clofazimine resistance. 
90
Breakpoints for bedaquiline are still provisional (10,11) and patients are started on treatment without 91 susceptibility tests. We adopted 0.25 mg·L −1 as susceptibility breakpoint in 7H10 and 7H11(12 ,13), which is 92 above the MIC that inhibits 90% of the isolates or strains (0.12 mg·L −1 ). However, with this breakpoint, the 
114
Pakistan.
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